Initial Focus
Sterile IV fluids
Sterile large-volume parenteral IV fluids intended for use across hospitals and other clinical environments, subject to manufacturing readiness and regulatory approval.
About Biogenix
Biogenix is a Zimbabwean pharmaceutical manufacturing company being developed to strengthen access to quality-assured essential medicines through modern technology, responsible manufacturing and a patient-centred approach.
Zimbabwe is intended to provide Biogenix’s manufacturing, regulatory and commercial launch base. The strategy seeks to build on the country’s pharmaceutical and healthcare skills base and its position relative to neighbouring SADC markets.
Biogenix aims to support domestic pharmaceutical industrialisation while developing the quality, distribution and country-specific regulatory capability needed for regional healthcare resilience. SADC is the principal regional market; additional African markets are a longer-term opportunity to evaluate after establishing this foundation.
This development direction does not imply government endorsement, incentives or guaranteed procurement.
Who We Are
Biogenix is being developed as a Zimbabwe-based pharmaceutical manufacturing platform, beginning with essential IV fluids and progressing into selected generic injectable medicines. Zimbabwe is the intended manufacturing and launch base, SADC the principal regional market, and wider Africa the long-term growth horizon.
The company’s first strategic platform is the proposed manufacture of large-volume parenteral IV fluids. Over time, Biogenix intends to develop a carefully selected portfolio of generic injectable medicines based on clinical need, technical feasibility, market requirements and regulatory approval.
Biogenix seeks to combine pharmaceutical science, appropriate manufacturing technology, rigorous quality systems and an understanding of healthcare needs to support more dependable access to essential medicines.

A focused direction shaped around medicines that hospitals, clinics and healthcare providers depend on.
Building appropriate technical, quality and production capability closer to the healthcare systems it is intended to support.
Developing responsibly in Zimbabwe with a long-term view toward suitable regional healthcare needs.
Our Purpose
Biogenix is being developed to help address the need for reliable access to essential hospital medicines through a focused, responsible manufacturing strategy.
Initial Focus
Sterile large-volume parenteral IV fluids intended for use across hospitals and other clinical environments, subject to manufacturing readiness and regulatory approval.
Long-Term Direction
Expansion into selected generic injectable medicines guided by healthcare needs, technical capability, market assessment and regulatory requirements.
Mission and Vision
Our mottoA Calling to Heal
What Guides Us
Every product ultimately serves a patient, and patient wellbeing must remain central to decision-making.
Quality should be designed into every stage of product development and manufacturing.
Biogenix seeks to operate with transparency, accountability and professional ethics.
Healthcare systems depend on consistent standards and dependable medicine supply.
Biogenix aims to use appropriate technology to improve manufacturing capability and product quality.
Progress requires constructive relationships with healthcare professionals, regulators, suppliers, technical partners and communities.
Biogenix seeks to create lasting value for patients, employees, communities and the environment.
Our Development Path
Each stage is dependent on the necessary technical, operational and regulatory requirements. The sequence does not indicate completion or a committed timeline.
Phase 1
Develop the Zimbabwe manufacturing platform; complete facility, process and quality preparation; obtain necessary regulatory authorisations; prepare the initial IV-fluid portfolio; and build domestic distribution relationships.
Phase 2
Increase utilisation subject to validated performance and demand; pursue registrations in selected neighbouring SADC markets; establish qualified regional distribution relationships; and develop the generic injectable programme.
Phase 3
Progress selected generic injectable medicines; evaluate additional sterile pharmaceutical products; broaden regional registrations and procurement participation; and build specialised commercial and regulatory capability.
Phase 4
Develop toward a multi-market pharmaceutical supplier; evaluate regional warehousing and distribution requirements; pursue appropriate regional procurement opportunities; and assess entry into additional African markets.
Responsible Growth
Biogenix aims to consider responsible practices as its proposed operations, supply relationships and future workforce are developed.
These themes express the direction being considered for Biogenix’s development. They are not claims of completed programmes, measured outcomes or environmental certification.
Work With Us
Biogenix welcomes conversations with healthcare institutions, technical partners, qualified suppliers, development partners and professionals interested in contributing to its manufacturing vision.